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Cancer is the second leading cause of death globally, only surpassed by cardiovascular diseases, with nearly 1 in 6 deaths due to cancer [1] . Following the discovery of the platinumbased drug cisplatin for treating cancer, a wide spectrum of platinum(II)-based complexes have been developed and are commercially available, e.g., carboplatin [2] . However, there are currently limitations to the clinical use of cisplatin and its analogues, e.g., dose-limiting toxicity and resistance [3] . Thus, there has been a surge in the development of alternative drugs without the demerits of platinum-based analogues. Notable examples include the ruthenium (II) compounds which have shown some promising results [4] . However, a key challenge in the development of metal-based drugs lies in understanding the drug-host interactions, in addition to the intrinsic properties of the complexes. Therefore, to have a better understanding of the mechanisms and mode of action of metallo-drugs, a combination of experimental and theoretical platforms is critical and is currently being explored. These include studying the kinetics of substitution reactions [5] with biologically relevant molecules, molecular docking [6] and DNA binding studies [7] .
As an illustration, Bratsos et al. established that anticancer activities of ruthenium (II) half sandwich complexes are directly related to the rate of hydrolysis of the complexes [8] . In a more recent study, the anti-cancer activities of two ruthenium(II) complexes, [Ru(Cltpy)(en)Cl][Cl] and Ru(Cl-tpy)(dach)Cl] [Cl] reveal that the lower rate of substitution of the coordinated chloride ligand with biologically relevant L-His in comparison to 5′-GMP is responsible for their anti-tumor activity due limited cytoplasmic deactivation [9] . An example where DNA binding and molecular docking has been used to interrogate the cytotoxicity of metal compounds is well presented in the recent report of Hong et al. [10] using enantiomeric ruthenium(II) complexes. A positive correlation between the binding affinities of the compounds to the DNA and their anti-cancer activities was observed. In this communication,
we report the application of a combination of kinetics of ligand substitution reactions, molecular docking and theoretical studies to investigate the anti-cancer activities of (pyrazolyl)pyridine ruthenium(III) compounds.
The compounds, 2-bromo-6-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (L1), 2,6-di (1H-pyrazol-1-yl) pyridine (L2) and 2,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (L3) ligands were synthesised following literature methods [11] . Reactions of L1-L3 with RuCl3·3H2O resulted in the formation of the corresponding ruthenium(III) metal complexes 1-3 in good yields (Scheme 1). Mass spectrometry, elemental analyses and single crystal X-ray analyses was used to characterize the complexes. For example, the ESI-MS mass spectrum of complex 3 ( Figure S1 ) showed a base peak at 439.01 amu, corresponding to the [Ru(L3)Cl2] + fragment.
The elemental analyses data of complexes 1-3 were in good agreement with one metal centre and one ligand motif as proposed in Scheme 1. While penta-coordinated Ru(III) complexes are rare, both the elemental analyses and MS (m/z = 424.85: M+ -Cl) data collected for complex 1 agree with the proposed structure. However, it is possible that the crystal structure of 1 may contain a solvent molecule in the sixth coordination sphere as we previously reported for similar Ru(III) complexes [12] .
Scheme 1: Syntheses of (pyrazolyl)pyridine ruthenium(III) complexes 1-3.
The molecular structure of complex 3 is shown in Figure 1 , while Table S1 Tables S5-S7 ) and are presented in Table 2 . Computational modelling of the ruthenium(III) complexes was performed in order to provide insight to kinetics data. The geometry optimised structures and the frontier orbitals are given in Table S8 while Comparing the rates of displacement of the coordinated chlorides by the thiourea nucleophile, the order of decreasing reactivity was found to be 1 > 2 > 3. The difference in reactivity can be concluded to be due to electronic effects. This is supported by the DFT calculations which shows that the electrophilicity of the complexes are in line with the trend of the rates of the substitution reactions. To try and understand the observed reactivity trend, it is important to reflect on the properties of the spectator ligand. The pyridine ring readily accepts π-back bonding from the metal, while pyrazole rings are π-electron rich because of the extra pyrazolyl-N which make them better σ-donors [15] [16] . This means that the pyrazole fragment has poor π-acceptor ability and good σ-donor ability. This property results in accumulation of electron density around the metal atom with a net reduction in the substitution of the chloro atom. In the present study, complex 1 is more reactive than 2 and 3 due to its higher electrophilicity compared to complexes 2 and 3, which contain an extra pyrazolyl motif.
Secondly, the pyridine ring has an electron withdrawing bromide group [17] and thereby, enhancing the π-back bonding ability of the ring. Comparing complexes 2 and 3, the controlling factor is the presence of the pyrazolyl methyl substituents in 3. This enhances the σ-donor ability of the pyrazole ring while reducing its π-acceptor properties and thus makes the metal centre to be the least electropositive as supported by the DFT calculations and elecetrophilicity values (ω). In addition, the DFT calculations also support the role of the π-back donation [18] Table S10 .
The docking results revealed that complexes 1-3 form stable complexes with DNA binding sites through non-covalent interactions [22] . The negative binding energies suggest that the complexes interact in a parallel manner with respect to the minor/major grooves of the DNA backbone. The resulting relative binding energies of 1, 2, and 3 with the DNA were obtained as -209.05 kJ/mol, -232.00 kJ/mol and -251.58 kJ/mol, respectively (Table S10) . Thus complex 
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